CareDx, Inc. regulatory filings document the public-company record for a Nasdaq-listed precision medicine company serving transplant patients and caregivers. The company’s 8-K and proxy materials cover operating and financial results for testing services, patient and digital solutions, laboratory products, and clinical or regulatory disclosures tied to non-invasive molecular testing for organ transplantation.
CareDx filings also address material agreements, capital-structure matters for its common stock, shareholder voting items, board governance, executive compensation, inducement and other equity awards, and officer-role changes. Other-event disclosures include governance and legal-contingency materials, including shareholder derivative litigation settlement documents when filed.
CareDx, Inc. reported that 997 shares of common stock were withheld from Secretary and General Counsel Jeffrey Adam Novack on October 1, 2026, to satisfy tax-withholding obligations connected with the issuance of shares upon vesting of restricted stock units. The reported price was $66.23 per share, and his direct holdings afterward were 105,078 shares.
CareDx, Inc. (CDNA) President and CEO John Walter Hanna Jr. had 8,511 shares withheld on October 1, 2026, to satisfy tax withholding obligations connected with the vesting of restricted stock units. He directly held 644,937 shares after the transaction.
CareDx, Inc. CFO & COO Keith Kennedy had 3,018 shares of common stock withheld by the issuer on October 1, 2026, to satisfy tax-withholding obligations connected with issuing shares upon vesting of restricted stock units. The reported price was $66.23 per share; his direct holdings after the transaction were 208,686 shares.
CareDx, Inc. Chief Commercial Officer Jessica Meng had 2,619 common shares withheld by the issuer on October 1, 2026, to satisfy tax withholding obligations tied to shares issued upon vesting of restricted stock units. The reported price was $66.23 per share; her direct holdings after the transaction were 158,980 shares.
CareDx, Inc. director Michael Goldberg acquired 588 shares of common stock on October 2, 2026, as an automatic quarterly grant in lieu of cash for non-employee director compensation under the issuer’s Outside Director Compensation Policy. After the grant, Goldberg directly held 62,326 shares. The Cavallo Trust held 91,045 shares; Goldberg and his spouse are trustees.
CareDx, Inc. (CDNA) filed an amended report to provide full historical financial statements for its newly acquired subsidiary Naveris, Inc. and related unaudited pro forma financial information. Naveris generated $34.3 million of revenue and a $3.9 million net loss in 2025, ending the year with $15.4 million in cash and a $65.0 million accumulated deficit. The independent auditor and Naveris management concluded there is substantial doubt about Naveris’ ability to continue as a going concern due to recurring losses and negative operating cash flows.
For the three months ended March 31, 2026, Naveris reported revenue of $10.8 million and a net loss of $0.8 million, with cash and cash equivalents of $14.3 million. Notes also disclose that on April 28, 2026 Naveris agreed to be acquired by CareDx for $160 million in upfront cash, plus up to $100 million contingent on specified revenue milestones, with closing expected in the third quarter of 2026, subject to customary conditions.
CareDx, Inc. (CDNA) reported that its CFO & COO, Keith Kennedy, had 8,220 shares of common stock withheld on September 12, 2026 to pay tax liabilities related to the vesting of restricted stock units. These shares were withheld by the company and not sold in the market. Following this tax-withholding transaction, Kennedy directly holds 211,704 shares of CareDx common stock.
CareDx, Inc. reported that Chief Commercial Officer Jessica Meng had 6,688 shares of common stock withheld on September 12, 2026 to satisfy tax withholding obligations related to vesting of restricted stock units. The shares were valued at $52.37 per share, leaving her with 161,599 shares held directly.
The transaction was a tax-withholding disposition effected by the issuer and not an open-market sale, and no Rule 10b5-1 trading plan is reported for this filing.
CareDx, Inc. insider Peter Maag filed a notice to sell 9,122 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services. The filing lists an aggregate market value of $423,091.13 for these shares and references 51,734,223 shares outstanding of CareDx common stock as of this notice.
The notice also reports prior sales of CareDx common stock by Peter Maag during August 2026, including transactions of 75,653 shares on August 4, 46,963 shares on August 5, and 27,332 shares on August 7, each with stated aggregate proceeds. Several tranches of restricted stock granted by the issuer between June 2023 and July 2024 are identified as the securities to be sold.
PETER MAAG filed to sell common stock of CDNA. The notice lists a proposed sale of 7,000 shares through Morgan Stanley Smith Barney LLC Executive Financial Services, with an aggregate market value of $317,112.60, against 51,734,223 shares outstanding as of the filing. It also details multiple common stock sales over the prior three months, including blocks of 75,653, 46,963, and 27,332 shares, each with corresponding dollar amounts.